Nanda Uitslager

Nanda Uitslager

Auto-generated profile, based on publicly available information

Nanda Uitslager

Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Haemophilia
Verified
Journal Article
Open access
NUNanda Uitslager
Nanda Uitslager
MKMary Kavanagh
Mary Kavanagh
MBMaj Birkedal
Maj Birkedal
LMLinda Myrin‐Westesson
Linda Myrin‐Westesson
Introduction: A nurse is one of the core members of the multidisciplinary haemophilia team. However, what people with inherited bleeding disorders (PwBD) can expect from them has not yet been formally defined. Aim: This project, initiated by the EAHAD Nurses Committee, aimed to establish Principles of Nursing Care (PoNC) for PwBD to promote high‐quality, consistent nursing care throughout the European Haemophilia Comprehensive Care Centres (EHCCC) and European Haemophilia Treatment Centres (EHTC). Methods/results: The PoNC were developed through a multi‐phase process, which included 10 roundtable meetings with input from expert nurses across Europe. The emerging PoNC were critically reviewed by members of the European Haemophilia Consortium (EHC), EAHAD Executive Committee, EAHAD Physiotherapists Committee and EAHAD Psychosocial Professionals Committee. Based on their feedback, the authors made further refinements, resulting in the final version of the PoNC. Conclusion: In summary, PwBD should have access to nurses who provide coordinated person‐centred care across all aspects of their lives. This includes education, treatment management, life‐stage support, surgical coordination, genetic counselling and special attention to the needs of women and girls. The nurses must also stay informed about research developments to ensure up‐to‐date care. The PoNC strengthen nursing care by providing a framework to address patient needs and may guide the development of care strategies, empowering patients and HCPs to advocate for high‐quality care. These principles promote standardised nursing care in EHCCC and EHTC, to be applied alongside local policies and EAHAD's accreditation standards.

7 October 2020 in TH Open
Verified
Journal Article
Open access
PDF file
MTMarissa J.M. Traets
Marissa J.M. Traets
KFKathelijn Fischer
Kathelijn Fischer
NUNanda Uitslager
Nanda Uitslager
PVPaul R. van der Valk
Paul R. van der Valk
IHIdske C.L. Kremer Hovinga
Idske C.L. Kremer Hovinga
RSRoger E.G. Schutgens
Roger E.G. Schutgens
Extended half-life (EHL) products have made their way to clinical practice in the treatment of hemophilia A and B. Phase-3 studies indicated a significantly prolonged terminal half-life (T1/2) of rFVIII-Fc and rFIX-Fc versus standard rFVIII and rFIX; 19.0 versus 12.4 hours (1.5-fold) for FVIII and 82.1 versus 33.8 hours (2.4-fold) for FIX.[1] [2] Several studies demonstrated a reduced infusion frequency, lower clotting factor consumption (CFC), and slightly lower annual bleeding rates (ABR).[3] [4] [5] The objective of this study was to evaluate the impact of switching from standard half-life (SHL) products to rFVIII-Fc (Efmoroctocog alfa, Elocta) and rFIX-Fc (Eftrenonacog alfa, Alprolix) on pharmacokinetics (PK), CFC, prophylactic infusion frequency, and ABR. This single center observational, retrospective study, conducted at the Van Creveldkliniek in Utrecht, the Netherlands, included patients of all ages who were treated previously with SHL products. The protocol was approved by the local Medical Ethical Committee. Data were collected and analyzed for 24 months before the switch and a mean of 16 months after the switch (range: 4–27 months). Patients were switched between 2016 and 2018. PK assessments (prophylactic dose, minimum three samples) were performed for minimum 3 days (FVIII) or maximum 7 days (FIX) using a kaolin-based one-stage (activated partial thromboplastin time) clotting assay for all assessments.[1] [2] Based on comparison with central laboratory data during phase-3 study participation, all measurements of Alprolix were multiplied by 2. Data were entered in the WAPPS-Hemo program, and balanced estimates of terminal half-life, time to reach 0.01 IU/mL (1%) FVIII/IX activity, area under the curve (AUC), clearance, and Cmax were extracted.[6] Prophylactic infusion frequencies were compared during 3 months before the transition and the last 3 months of observation after the transition. Data on CFC were extracted from pharmacy records combined with reported home stocks and patient diaries. The ABR was calculated based on the full follow-up period. Data were analyzed using descriptive statistical methods, including means, medians, 95% confidence interval, and inter–quartile ranges (IQR). Groups were compared using the Wilcoxon sign-rank test and paired-samples t-test. In total 34 severe hemophilia patients switched to EHL. Four patients were excluded due to immune tolerance induction (n = 1) and missing data (n = 3). Eventually, 30 patients were analyzed, including 50% with hemophilia A. Median age was 35 years (range: 5–79), including 11 children (<18 years). Seven patients (six hemophilia A) had a history of inhibitors. Treatment characteristics and bleeding before and after switching to EHL are shown in [Table 1]. T1/2 of rFVIII-Fc was extended 1.4-fold compared with rFVIII (p = 0.004). T1/2 of rFIX-Fc was extended 2.6-fold compared with rFIX (p = 0.005). A subgroup analysis showed shorter T1/2 for both rFVIII-Fc and rFIX-Fc in ex-inhibitor patients, with comparable half-life extension. Extension of T1/2 was age dependent: in children, T1/2 was extended 1.3-fold for rFVIII-Fc and 2.1-fold for rFIX-Fc versus 1.6- and 2.7-fold, respectively, in adults. The median time above 1% FVIII/IX activity after a prophylactic infusion was extended by 1.5 days for hemophilia A (p = 0.002) and by 10.2 days for hemophilia B (p = 0.005). After switching to EHL concentrates, the mean annual CFC dropped 10% in hemophilia A and 29% in hemophilia B patients, p = 0.04 (absolute numbers in [Table 1]). A clinically relevant reduction of ≥10% was seen in 7 of 14 hemophilia A and in 7 of 13 hemophilia B patients ([Fig. 1]). Children showed a more pronounced reduction in CFC than adults, especially children with hemophilia B. Prophylactic infusion frequency was reduced in a minority (4/15: 26.7%) of hemophilia A patients and in almost all (14/15, 93.3%) patients with hemophilia B, who were all able to infuse rFIX-Fc once weekly. ABR decreased in adults with hemophilia A only, from 4.0 to 2.1, (p = 0.05). For patients with hemophilia B, a trend toward ABR reduction was observed in children only, from 3.5 to 2.5, (p = 0.08). This study demonstrates that the switch resulted in an extension of the terminal half-life of rFVIII-Fc (1.4-fold) and rFIX-Fc (2.6-fold) and a significant prolongation of the time to reach a trough level of 1% (1.5 days for hemophilia A and 10.2 days for hemophilia B) with a higher AUC. The infusion frequency of patients with hemophilia A remained stable. The resulting higher and more stable trough levels are expected to provide better protection against bleeds. The A-LONG phase-3 study in hemophilia A included 28 patients with hemophilia A >12 years who underwent PK assessments compared with 15 patients in our study (including 5 <12 years).[1] The T1/2 increase of rFVIII-Fc in our real-life study (1.4-fold) was comparable with the phase-3 study (1.5-fold), as was the time to reach a trough level of 1% (4.2 vs. 4.9 days). For hemophilia B, the B-LONG phase-3 study included 22 patients aged >12 years who underwent PK assessments compared with 15 patients in our study (including 2 <12 years).[2] The T1/2 increase of rFIX-Fc in our real life experience (2.6-fold) was similar to the phase-3 study (2.4-fold). Although the time to reach a trough level of 1% appeared longer in our study (17.4 vs. 11.2 days). This may be explained by differences in modeling and/or the shorter sampling time: 168 versus 240 hours in the phase 3-study. In patients <18 years, T1/2 observed (76.1 hours) was similar to the kids B-LONG study (68.6 hours).[7] Our switching protocol was prespecified and included standard testing, using prophylactic dosing to reflect the real-life experience and patient relevant outcomes. The present study had much longer follow-up than other real-life studies by Keepanasseril et al (6 months pre- and postswitch)[3] and Wang and Young (1 year...

1 January 2020 in The Journal of Haemophilia Practice
Verified
Journal Article
Open access
PDF file
GMGreta Mulders
Greta Mulders
NUNanda Uitslager
Nanda Uitslager
SASharon Alavian
Sharon Alavian
AWAnne Wareing
Anne Wareing
KOKathi Stein Oldenburg
Kathi Stein Oldenburg
Introduction: Switching between clotting factor products is becoming increasingly common as product choice increases and financial pressure grows to choose the most cost-effective options. Guidance on carrying out the switch recommends a complex and long process that may benefit from being defined in a protocol. Haemophilia nurses may be responsible for managing product switches; anecdotal evidence suggests that clinical practice is variable. Aim: To explore the role of specialist nurses in switching between clotting factor products and their use of a protocol. Method: Nurses attending the 2018 World Federation of Hemophilia Congress were surveyed about clinical practice at their treatment centre and use of a protocol for switching clotting factor products. Results: Of 192 nurses attending the conference, 49 nurses returned completed questionnaires, 45 of which were included in the study after exclusions. Responses were exclusively from economically developed countries. Almost all respondents (96%) had direct experience of switching. Half of those who responded to a question about protocol-based switching reported that switches were based on a protocol. When authorship was reported, the protocol was written by haemophilia nurses in about half of cases. Practice about blood testing to determine individual pharmacokinetic parameters prior to the switch was variable, but most nurses (86%) reported screening for inhibitors prior to switching. Respondents agreed to share their protocols among their peers, although only four were received by the research team. Conclusions: Clinical practice in switching between clotting factor products is variable. Some nurses are switching treatments for patients without the supported of a written protocol, whereas others are involved in writing and implementing protocols. Sharing protocols is a first step in helping to establish best practice.

1 January 2016 in The Journal of Haemophilia Practice
Verified
Journal Article
Open access
GMGreta Mulders
Greta Mulders
NUNanda Uitslager
Nanda Uitslager
The Verpleegkundigen & Verzorgenden Nederland Verpleegkundig Specialisten (V&VN VS), the Dutch professional organisation representing nurse practitioners, has introduced a requirement for advanced practice (registered) nurses (APRN) who wish to be eligible for reregistration within five years to participate in a peer review group for at least eight hours per year. In 2013, five APRNs caring for people with haemophilia and other bleeding disorders in the Netherlands formed a peer review group. As no framework was available, research was undertaken through reviewing literature and engaging in exploratory discussions within the profession in order to identify best practice in establishing such a group. The initial meeting of the new peer review group agreed possible methodologies and established meeting rules. After four meetings, some initial conclusions can now be drawn on the benefits of this specialised haemophilia peer review group. Overall, it is clear that participation in a forum in which knowledge and expertise are shared, contributes to the professionalism of the APRN.

1 January 2021 in The Journal of Haemophilia Practice
Verified
Journal Article
Open access
PDF file
SCSteve Chaplin
Steve Chaplin
MBMaj Friberg Birkedal
Maj Friberg Birkedal
ECErica Crilly
Erica Crilly
SFSimon Fletcher
Simon Fletcher
SBSara García Barcenilla
Sara García Barcenilla
NUNanda Uitslager
Nanda Uitslager
Introduction: Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes. Current clinical practice reduces the risk of bleeds, making differences difficult to measure. We surveyed specialist haemophilia nurses to discern their opinions about the impact of haemophilia B compared to haemophilia A. Methods: Between July and September 2020, European and Canadian nurses were invited to complete an online survey (25 questions) about perceptions of management and treatment of haemophilia B. Results: Fifty-nine nurses (46 European, 13 Canadian) completed the survey. Bleeding was reported as different in haemophilia B by 37% of respondents, and treatment as different by over half. Opinions and experience around using extended half-life (EHL) products varied. Self-reported confidence in using EHL products was rated at a mean of 7.1 (range 3–10) with 47% believing these would remain the optimal treatment in 2025. Conclusion: Some nurses believe haemophilia A and B are managed differently. Variations in experience and levels of confidence in the use of EHL products, combined with a belief that these products will remain an optimal treatment for haemophilia B for the next five years, indicates a need for education to promote confidence and competence.